Merrill Lynch Upgrades Amylin Pharmaceuticals (AMLN) to Buy
Merrill Lynch upgrades Amylin Pharmaceuticals (Nasdaq: AMLN) from Neutral to Buy.
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases.
Related Categories
UpgradesStocks Mentioned
Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
